Floatz logo

Acalabrutinib

Grade 3a Follicular Lymphoma

Patrick C. Johnson, MDSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Grade 3a Follicular Lymphoma cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Acalabrutinib is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
75 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →